GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Optipharm Co Ltd (XKRX:153710) » Definitions » EV-to-Revenue

Optipharm Co (XKRX:153710) EV-to-Revenue : 5.50 (As of May. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Optipharm Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Optipharm Co's enterprise value is ₩95,471 Mil. Optipharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₩17,373 Mil. Therefore, Optipharm Co's EV-to-Revenue for today is 5.50.

The historical rank and industry rank for Optipharm Co's EV-to-Revenue or its related term are showing as below:

XKRX:153710' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.58   Med: 8.75   Max: 28.58
Current: 5.5

During the past 11 years, the highest EV-to-Revenue of Optipharm Co was 28.58. The lowest was 3.58. And the median was 8.75.

XKRX:153710's EV-to-Revenue is ranked worse than
67.12% of 222 companies
in the Medical Diagnostics & Research industry
Industry Median: 3.195 vs XKRX:153710: 5.50

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-15), Optipharm Co's stock price is ₩6890.00. Optipharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₩1,183.41. Therefore, Optipharm Co's PS Ratio for today is 5.82.


Optipharm Co EV-to-Revenue Historical Data

The historical data trend for Optipharm Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optipharm Co EV-to-Revenue Chart

Optipharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.91 15.51 8.50 5.87 5.61

Optipharm Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.87 6.49 6.46 6.10 5.61

Competitive Comparison of Optipharm Co's EV-to-Revenue

For the Diagnostics & Research subindustry, Optipharm Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optipharm Co's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Optipharm Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Optipharm Co's EV-to-Revenue falls into.



Optipharm Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Optipharm Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=95471.371/17372.568
=5.50

Optipharm Co's current Enterprise Value is ₩95,471 Mil.
Optipharm Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩17,373 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optipharm Co  (XKRX:153710) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Optipharm Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6890.00/1183.406
=5.82

Optipharm Co's share price for today is ₩6890.00.
Optipharm Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,183.41.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Optipharm Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Optipharm Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Optipharm Co (XKRX:153710) Business Description

Traded in Other Exchanges
N/A
Address
6, 63 Osong, Hwaseong-eup, Heungduk-gu, Chungcheongbuk-do, Cheongju, KOR
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.

Optipharm Co (XKRX:153710) Headlines

No Headlines